- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00304408
Association Between Response to Treatment of C. Diff Colitis and Anti-C.Diff Toxin Antibody
September 9, 2010 updated by: Michael E. DeBakey VA Medical Center
Association Between Clinical Response of Clostridium Difficile Colitis to Treatment and Emergence of Anti-C.Difficile Toxin Antibody
The purpose of this study is three fold: 1)To collect serum from patients with documented Clostridium difficile infection and test for the presence of antibody to C. difficile toxin at the start and at the end of therapy, and again if a relapse or recurrence occurs.
2)To collect stool samples for test of C. difficile toxin at similar time intervals.
3)To assay random serum samples from the VA lab in order to determine the rate of antibody to C. difficile toxin in our patient population.
Study Overview
Status
Completed
Detailed Description
Clostridium difficile is the leading cause of nosocomial diarrheal disease associated with antibiotic therapy.
This is a debilitating condition with substantial morbidity and mortality that may be around 2-3%.
Current recommended therapy for this condition is metronidazole, given orally.
Our observations suggest that about 10-20% of patients fail to respond to initial therapy with metronidazole, and 20% relapse after treatment.
The reason why some persons are cured whereas others relapse is, at present, unknown.
There is a suggestion in the medical literature that recurrent infection is associated with the failure to generate antibody to C. difficile toxin.
It is also possible that those patients who become infected lack antibody, whereas others in the population tend to have such antibody.
The investigators propose to study our patients at VAMC Houston in order to relate occurrence and/or the failure to respond to therapy or the appearance of recurrent disease to the presence of anti-toxin antibody.
The investigators also propose to study sera obtained at random from VAMC patients in order to determine the prevalence of antibody in our patient population.
Study Type
Observational
Enrollment (Actual)
10
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- Michael E. DeBakey VA Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients positive for C. difficile.
Description
Inclusion Criteria:
- All patients at the Houston VA with documented C. difficile infection
Exclusion Criteria:
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Daniel M Musher, M.D., Michael E. DeBakey VA Medical Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2005
Primary Completion (Actual)
January 1, 2008
Study Completion (Actual)
January 1, 2008
Study Registration Dates
First Submitted
March 16, 2006
First Submitted That Met QC Criteria
March 16, 2006
First Posted (Estimate)
March 17, 2006
Study Record Updates
Last Update Posted (Estimate)
September 10, 2010
Last Update Submitted That Met QC Criteria
September 9, 2010
Last Verified
September 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-16383
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Clostridium Enterocolitis
-
Michael E. DeBakey VA Medical CenterBaylor College of MedicineCompletedClostridium Enterocolitis | Pseudomembranous Colitis | Antibiotic-Associated ColitisUnited States
-
José María Aguado García, MD, PhDMerck Sharp & Dohme LLC; Hospital Universitario 12 de OctubreCompletedEnterocolitis, Pseudomembranous | Clostridium DifficileSpain
-
Daniel M. Musher MDBaylor College of MedicineCompletedClostridium Enterocolitis | Pseudomembranous ColitisUnited States
-
Genzyme, a Sanofi CompanyCompletedDiarrhea | Clostridium EnterocolitisAustralia, Belgium, France, Spain, Germany, Portugal, Switzerland, Austria, United Kingdom, Ireland, Czech Republic, Denmark, Norway, Sweden
-
Jewish General HospitalTerminatedFulminant Clostridium Difficile ColitisCanada
-
Genzyme, a Sanofi CompanyCompletedClostridium Difficile-Associated Diarrhea | Antibiotic-associated Diarrhea | Clostridium Enterocolitis | Clostridium Difficile Diarrhea | Antibiotic-associated ColitisUnited States, Canada, United Kingdom, Puerto Rico
-
William Beaumont HospitalsTerminatedClostridium Difficile ColitisUnited States
-
McMaster UniversityThe Physicians' Services Incorporated FoundationCompletedAntibiotic-Associated Diarrhea | Clostridium Enterocolitis | Pseudomembranous Colitis | Pseudomembranous Enterocolitis | Pseudomembranous EnteritisCanada
-
Massachusetts General HospitalTerminatedClostridium Difficile ColitisUnited States
-
Duke UniversityRecruitingClostridium Difficile ColitisUnited States